Holen Sie sich die Stockscreener-App
31.68
11.00%
3.14
Vorhandelsmarkt:
33.00
1.32
+4.17%
Schlusskurs vom Vortag:
$28.54
Offen:
$28.6
24-Stunden-Volumen:
30,978
Relative Volume:
0.06
Marktkapitalisierung:
$193.33M
Einnahmen:
-
Nettoeinkommen (Verlust:
$-7.12M
KGV:
-13.77
EPS:
-2.3
Netto-Cashflow:
$-6.82M
1W Leistung:
+26.82%
1M Leistung:
+22.70%
6M Leistung:
+4,593%
1J Leistung:
+8,544%
1-Tages-Spanne:
$28.60
$32.52
1-Wochen-Bereich:
$24.00
$32.52
52-Wochen-Spanne:
$0.309
$38.50
Monopar Therapeutics Inc Stock (MNPR) Company Profile
Firmenname
Monopar Therapeutics Inc
Sektor
Branche
Telefon
(847) 388-0349
Adresse
1000 SKOKIE BLVD SUITE 350, WILMETTE
Vergleichen Sie MNPR mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
MNPR
Monopar Therapeutics Inc
|
31.68 | 193.33M | 0 | -7.12M | -6.82M | -2.30 |
|
VRTX
Vertex Pharmaceuticals Inc
|
427.89 | 110.19B | 10.63B | -479.80M | -1.35B | -1.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
687.80 | 75.58B | 13.85B | 4.65B | 3.32B | 40.41 |
|
ARGX
Argen X Se Adr
|
647.39 | 38.71B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
264.99 | 34.18B | 2.09B | -332.26M | 16.06M | -2.62 |
|
BNTX
Biontech Se Adr
|
117.25 | 28.11B | 3.30B | -501.07M | 1.03B | -2.1146 |
Monopar Therapeutics Inc Stock (MNPR) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-01-10 | Eingeleitet | Piper Sandler | Overweight |
| 2024-10-11 | Eingeleitet | Rodman & Renshaw | Buy |
| 2021-01-28 | Eingeleitet | ROTH Capital | Buy |
Monopar Therapeutics Inc Aktie (MNPR) Neueste Nachrichten
All You Need to Know About Monopar Therapeutics (MNPR) Rating Upgrade to Buy - MSN
(MNPR) Trading Report - Stock Traders Daily
Up 1,000% in 2024, Wall Street Believes This Growth Stock Can Still Skyrocket - TradingView
Piper Sandler Begins Coverage on Monopar Therapeutics (NASDAQ:MNPR) - Defense World
Piper Sandler Initiates Coverage of Monopar Therapeutics (MNPR) with Overweight Recommendation - MSN
(MNPR) Trading Advice - Stock Traders Daily
Piper Sandler Initiates Coverage on Monopar Therapeutics (NASDAQ:MNPR) - MarketBeat
Brookline Capital Management Comments on MNPR Q1 Earnings - Defense World
Brookline Capital Management Predicts MNPR Q1 Earnings - MarketBeat
JANUS HENDERSON GROUP PLC Acquires Additional Shares in Monopar Therapeutics Inc - GuruFocus.com
MNPR Stock Skyrockets 384% in 3 Months After Deal With AZN - MSN
How the (MNPR) price action is used to our Advantage - Stock Traders Daily
These 2 Monster Growth Stocks Skyrocketed Over 1,000% This Year — Here’s What Analysts Expect in 2025 - Yahoo Finance
Monopar Therapeutics Inc. Enters Into Underwritten Registered Offering and Concurrent Private PlacementOn December 20, 2024, Monopar Therapeutics Inc. (NASDAQ: MNPR) finalized an Underwriting Agreement with Piper Sandler & Co. to conduct an Und - Defense World
What Awaits These 4 Biotech Stocks That More Than Doubled in 2024 - Zacks Investment Research
Monopar: Radiopharmaceutical Company With 2 Radioisotope Development Pathways (MNPR) - Seeking Alpha
(MNPR) Technical Data - Stock Traders Daily
Monopar Therapeutics announces pricing of $40M public offering of common stock - MSN
Best-Performing Small-Cap Stocks of 2024 - Investing.com
Monopar Therapeutics Inc. Announces Pricing of $40 Million Public Offering of Common Stock and Concurrent Private Placement of Pre-Funded Warrants - The Manila Times
Monopar Therapeutics sets stock and warrant offering prices - Investing.com
Here's What Could Help Monopar Therapeutics (MNPR) Maintain Its Recent Price Strength - MSN
When the Price of (MNPR) Talks, People Listen - Stock Traders Daily
Monopar Therapeutics Achieves Milestone in Cancer Treatment - TipRanks
Monopar Announces First Patient Dosed with its Novel Therapeutic Radiopharmaceutical MNPR-101-Lu - EIN News
Monopar Therapeutics Inc. Doses First Patient with its Novel Therapeutic Radiopharmaceutical MNPR-101-Lu - Marketscreener.com
Oral Mucositis Market expected to rise | Companies- Galera Therapeutics, Soligenix, Izun Pharma, MitoImmune Therapeutics, Tosk, Cellix Bio, Enzychem Lifesciences, Monopar Therapeutics - The Globe and Mail
What Makes Monopar Therapeutics (MNPR) a Good Fit for 'Trend Investing' - MSN
Monopar to Present at the 36th Annual Piper Sandler Healthcare Conference - The Manila Times
3 Momentum Stocks Soaring Into 2025 and Beyond - sharewise
Monopar Therapeutics: Radiopharmaceuticals And Rare Disease Potential In Focus - Seeking Alpha
(MNPR) Proactive Strategies - Stock Traders Daily
HC Wainwright Has Positive Estimate for MNPR FY2024 Earnings - MarketBeat
HC Wainwright Issues Positive Forecast for Monopar Therapeutics (NASDAQ:MNPR) Stock Price - MarketBeat
Monopar Therapeutics stock target lifted, buy rating on AstraZeneca deal By Investing.com - Investing.com UK
Monopar Therapeutics (NASDAQ:MNPR) Releases Financial Results for the Third Quarter 2024Monopar Therapeutics Inc. recently disclosed its financial results for the third quarter ending September 30, 2024, in a press release dated November 8, 2024. The - Defense World
MNPRMonopar Therapeutics Inc. Latest Stock News & Market Updates - StockTitan
(MNPR) Investment Report - Stock Traders Daily
Monopar Therapeutics Inc Reports Q3 2024 GAAP EPS of -$0.37 and Net Loss of $1.3 Million - GuruFocus.com
Monopar Therapeutics Reports Third Quarter 2024 Financial Results and Recent Developments - The Manila Times
Monopar Therapeutics Reports Third Quarter 2024 Financial Results and Recent Developments - GlobeNewswire Inc.
Janus Henderson Group PLC Acquires New Stake in Monopar Therapeu - GuruFocus.com
RA Capital Management, L.P. Acquires New Stake in Monopar Therap - GuruFocus.com
Monopar Therapeutics Inc. Announces Closing of $19.2 Million Public Offering of Common Stock - The Manila Times
Insider Purchase: CFO Karthik Radhakrishnan Acquires Shares of M - GuruFocus.com
Monopar Therapeutics Closes $19.2 Million Stock Offering - TipRanks
Monopar Therapeutics drops 16%, prices $19M offering at $16.25 per share - MSN
(MNPR) Investment Analysis - Stock Traders Daily
Finanzdaten der Monopar Therapeutics Inc-Aktie (MNPR)
Umsatz
Nettogewinn
Free Cashflow
ENV
Monopar Therapeutics Inc-Aktie (MNPR) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| Cittadine Andrew | Chief Operating Officer |
Jun 20 '24 |
Buy |
0.74 |
20,508 |
15,254 |
186,132 |
| Cittadine Andrew | Chief Operating Officer |
Jun 18 '24 |
Buy |
0.86 |
12,000 |
10,320 |
165,624 |
| Cittadine Andrew | Chief Operating Officer |
Jun 14 '24 |
Buy |
0.93 |
12,000 |
11,176 |
141,624 |
| Cittadine Andrew | Chief Operating Officer |
Jun 13 '24 |
Buy |
0.91 |
12,000 |
10,920 |
129,624 |
| Cittadine Andrew | Chief Operating Officer |
Jun 17 '24 |
Buy |
0.90 |
12,000 |
10,799 |
153,624 |
| Cittadine Andrew | Chief Operating Officer |
Jun 04 '24 |
Buy |
0.78 |
12,000 |
9,360 |
117,624 |
| Cittadine Andrew | Chief Operating Officer |
Jun 03 '24 |
Buy |
0.76 |
12,000 |
9,120 |
105,624 |
| Cittadine Andrew | Chief Operating Officer |
May 31 '24 |
Buy |
0.64 |
12,000 |
7,732 |
93,624 |
| Cittadine Andrew | Chief Operating Officer |
May 30 '24 |
Buy |
0.64 |
12,000 |
7,676 |
81,624 |
| Cittadine Andrew | Chief Operating Officer |
May 29 '24 |
Buy |
0.64 |
12,000 |
7,643 |
69,624 |
4.81%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):